Press release
Amyotrophic Lateral Sclerosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock
Amyotrophic Lateral Sclerosis (ALS) Pipeline Insight 2025
Amyotrophic Lateral Sclerosis Pipeline constitutes 75+ key companies continuously working towards developing 80+ Amyotrophic Lateral Sclerosis treatment therapies, analyzes DelveInsight.
Amyotrophic Lateral Sclerosis Overview:
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative condition that primarily targets motor neurons. The disease can arise from both genetic (familial) and non-genetic (sporadic) factors, though a single definitive cause has not been identified. ALS typically impacts both upper and lower motor neurons, beginning with limb weakness and gradually progressing to paralysis and, ultimately, death.
The underlying cause of sporadic ALS remains largely unknown, though several mechanisms have been proposed, including disrupted RNA processing, oxidative stress from SOD1 mutations, inflammation, and glutamate toxicity. Familial ALS, which is less common, is linked to inherited genetic mutations such as expansions in the C9ORF72 gene and SOD1 gene mutations, typically passed down in an autosomal dominant manner.
Breathing difficulties are a major concern in ALS due to respiratory muscle weakening. Noninvasive ventilation is commonly used to manage symptoms like shortness of breath or reduced forced vital capacity (FVC), while invasive ventilation may be required in more severe cases. Difficulty swallowing (dysphagia) is also frequent and may be managed through dietary modifications or, if necessary, feeding via a gastrostomy (G-tube) to prevent weight loss.
ALS can lead to various complications, including respiratory failure, speech and mobility issues, malnutrition, fatigue, muscle spasms, and problems with saliva and mucus control. Additionally, medications used to manage ALS symptoms may cause side effects such as gastrointestinal discomfort, liver complications, or headaches.
Request for a detailed insights report on Amyotrophic Lateral Sclerosis pipeline insights @ https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Amyotrophic Lateral Sclerosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Amyotrophic Lateral Sclerosis Therapeutics Market.
Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report
*
DelveInsight's Amyotrophic Lateral Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Amyotrophic Lateral Sclerosis treatment.
*
In November 2025, Ractigen Therapeutics announced that its siRNA therapy RAG-21, which targets ALS associated with FUS gene mutations, received Orphan Drug Designation from the FDA.
*
Key Amyotrophic Lateral Sclerosis companies such as Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, and others are evaluating new drugs for Amyotrophic Lateral Sclerosis to improve the treatment landscape.
*
Promising Amyotrophic Lateral Sclerosis pipeline therapies in various stages of development include MN-166, RNS60, VM202, QRL-201, and others.
Amyotrophic Lateral Sclerosis Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Amyotrophic Lateral Sclerosis Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Amyotrophic Lateral Sclerosis treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Amyotrophic Lateral Sclerosis market.
Download our free sample page report on Amyotrophic Lateral Sclerosis pipeline insights @ https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Amyotrophic Lateral Sclerosis Emerging Drugs
*
MN-166: MediciNova
*
RNS60: Revalesio
*
VM202: Helixmith
*
QRL-201: QurAlis Corporation
Amyotrophic Lateral Sclerosis Companies
More than 75 major companies are actively involved in developing treatments for Amyotrophic Lateral Sclerosis (ALS). Among them, MediciNova has drug candidates in the most advanced stages of development, currently in Phase II/III clinical trials.
DelveInsight's report covers around 80+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Amyotrophic Lateral Sclerosis Therapies and Key Companies: Amyotrophic Lateral Sclerosis Clinical Trials and advancements [https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Amyotrophic Lateral Sclerosis Pipeline Therapeutic Assessment
- Amyotrophic Lateral Sclerosis Assessment by Product Type
- Amyotrophic Lateral Sclerosis By Stage
- Amyotrophic Lateral Sclerosis Assessment by Route of Administration
- Amyotrophic Lateral Sclerosis Assessment by Molecule Type
Download Amyotrophic Lateral Sclerosis Sample report to know in detail about the Amyotrophic Lateral Sclerosis treatment market @ Amyotrophic Lateral Sclerosis Therapeutic Assessment [https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Amyotrophic Lateral Sclerosis Current Treatment Patterns
4. Amyotrophic Lateral Sclerosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Amyotrophic Lateral Sclerosis Late-Stage Products (Phase-III)
7. Amyotrophic Lateral Sclerosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Amyotrophic Lateral Sclerosis Discontinued Products
13. Amyotrophic Lateral Sclerosis Product Profiles
14. Amyotrophic Lateral Sclerosis Key Companies
15. Amyotrophic Lateral Sclerosis Key Products
16. Dormant and Discontinued Products
17. Amyotrophic Lateral Sclerosis Unmet Needs
18. Amyotrophic Lateral Sclerosis Future Perspectives
19. Amyotrophic Lateral Sclerosis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Amyotrophic Lateral Sclerosis Pipeline Reports Offerings [https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=amyotrophic-lateral-sclerosis-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-ionis-pharmaceuticals-1st-biotherapeutics-scholar-rock]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Amyotrophic Lateral Sclerosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock here
News-ID: 4084079 • Views: …
More Releases from ABNewswire
Glioblastoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Trea …
DelveInsight's, "Glioblastoma- Pipeline Insight, 2025" report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, the Glioblastoma treatment pipeline includes over 180 key companies actively…
Alzheimer's Disease Clinical Trials, Companies, Therapeutic Assessment, Therapie …
DelveInsight's, "Alzheimer's disease- Pipeline Insight, 2025" report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Alzheimer's disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, the Alzheimer's Disease treatment pipeline includes over 110…
Acute Lymphocytic Leukemia Clinical Trials, Companies, Therapeutic Assessment, T …
DelveInsight's, "Acute Lymphocytic Leukemia (ALL) - Pipeline Insight, 2025," report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in Acute Lymphocytic Leukemia (ALL) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, the Acute Lymphocytic…
Iron Deficiency Anemia Market Poised for Robust Growth Through 2034, Driven by R …
The iron deficiency anemia treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players, including Akebia, Shield Therapeutics, AMAG Pharmaceuticals, Nemysis, Pharmacosmos Therapeutics, CSL Vifor, American Regent, JW Pharmaceutical, and Zeria Pharmaceutical, among others.
DelveInsight's "Iron Deficiency Anemia Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/iron-deficiency-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers an in-depth understanding of the iron deficiency anemia treatment market, historical and…
More Releases for Late
Desperate Puppy Seeks Rescue Before It’s Too Late!
FOR IMMEDIATE RELEASE
Tucson AZ, December 14th, 2021
The StarBarksCoffee.com rescue team was recently assaulted and threatened with being shot for assisting an abused, entangled puppy.
This Video of a neglected puppy desperately seeking rescue from a mentally unstable and violently aggressive owner was taken recently at an RV park in Texas during our annual "Journey Across America" in support of Animal Welfare.
We've contacted Texas authorities, but the Sheriff’s Department informed us the…
Transform your Traditional Businesses Before Its Too Late
Mob Inspire, an app development company has disrupted many industries by providing innovative software solutions to traditional businesses. We understand the rapidly changing tech environment and therefore equipt ourselves with those skills and tech tools which enable us to deal with challenging situations efficiently.
Mob Inspire takes the leverage of the latest tech trends like Blockchain, IoT and Cloud to deliver high-end products to its clients. The popularity…
May Tax Offices Collect 6% Interest for Late Payments
The 0% interest policy of the European Central Bank and German tax offices can still demand 6% default interest for late payments. How can this be? Is that not a crying injustice? The authorities collect 6% interest and all tax payers are punished when they save money in bank accounts with, for example, -1% interest. The Federal Fiscal Court ruled on this matter on November 09, 2017 (re III R…
Late-Night Treats for Late-Night Peeps
WHAT: La Motta’s, the neighborhood favorite in Boston’s SoWa District, is rolling out the late-night red carpet for its hospitality industry folks and friends, with Chef de Cuisine Justin Winter’s creative twists on after-hours snacks. Available every Sunday - Thursday from 10:00PM to last call, La Motta’s is the neighborhood joint for a late-night bash with flavorful bites and brews.
Launching Sunday, February 26th, 2017, guests can expect flavorful options…
Late payment – the hidden challenge facing Europe's businesses
A recent Europe-wide business survey has revealed no improvement in the pressure on European businesses from customers’ late payments, with 55 per cent of businesses across Europe reporting late payments resulting in loss of income, 63 per cent claiming additional pressures on liquidity, and 50 per cent citing late payments as having a direct impact on company growth.
In the Republic of Ireland, 47 per cent of businesses surveyed claimed…
Construction in Bulgaria to stabilise in late 2011
In the coming years Bulgaria's construction sector will start to grow slowly following the hard years of the economic slowdown, although no spectacular changes are expected in the short run. After substantial restructuring of the sector moderate construction market recovery in the period 2012-2013 is expected. Until 2015 the sector will grow on the back of the large-scale infrastructure projects related to EU funds.
According to the report “Construction sector in…
